Comparison
CJC-1295 vs. GHRP-6
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
no data
87616-84-0
Molecular weight
3647.3 g/mol
873.02 g/mol
Half-life
144 h
0.4 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACHis-D-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
4
of which in humans
3
2
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
3
2
Legal status
Full entries
Frequently asked questions
- What is the difference between CJC-1295 and GHRP-6?
- CJC-1295 is classified as "Growth", while GHRP-6 is classified as "Growth". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. GHRP-6: Synthetic hexapeptide that founded the class of growth-hormone-releasing peptides (GHRPs). Cyril Bowers identified GHRP-6 in the late 1970s as the first orally and parenterally active GH secretagogue with no structural similarity to GHRH. Never approved as a medicine; downstream analogs (GHRP-2, hexarelin, ipamorelin) were pursued clinically. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CJC-1295 or GHRP-6?
- The highest available evidence level is "Human trial" for CJC-1295 and "Human trial" for GHRP-6. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CJC-1295 and GHRP-6 in Germany and the United States?
- Germany: CJC-1295 — Unapproved, GHRP-6 — Unapproved. United States: CJC-1295 — Research only, GHRP-6 — Unapproved. These are factual summaries with source and review date on the individual pages.